Attached files
file | filename |
---|---|
8-K - NOVAVAX INC | v192705_8k.htm |
EX-99.1 - NOVAVAX INC | v192705_ex99-1.htm |
Contact:
|
Frederick
W. Driscoll
|
VP, Chief Financial Officer and
Treasurer
Novavax, Inc.
1-240-268-2000
NOVAVAX
Elects Richard H. Douglas to its Board of Directors
Rockville,
MD – August 6, 2010 – Novavax, Inc. (Nasdaq: NVAX) announced today the
appointment of Richard Douglas, Ph.D. to its board of directors. Dr.
Douglas is currently Senior Vice President, Corporate Development at Genzyme
Corp. As a leader of Genzyme’s Corporate Development team, Dr.
Douglas has been involved in numerous acquisitions, licenses, joint ventures and
strategic alliances as well as Genzyme’s venture investments. He has
served in a variety of corporate and product development positions with Genzyme
since he joined Integrated Genetics (now Genzyme) as a staff scientist in
1982.
Novavax
Chairman Stanley Erck stated: “Richard has more than twenty-five
years of corporate, business and product development experience at Genzyme which
will be extremely valuable to Novavax as we advance our vaccine
candidates. His expertise in business development, technology
assessment and protein chemistry will be especially helpful in guiding our
future discovery, development and commercialization programs. We
welcome his counsel and contributions to our future success.”
Dr.
Douglas currently serves on the national advisory board of the University of
Michigan Technology Transfer Office and previously served as a director of Iomai
Corporation and Synthon Chiragenics. He received his doctorate in
biochemistry from the University of California at Berkeley and his bachelor’s
degree in chemistry from the University of Michigan.
About
Novavax
Novavax,
Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to
address a broad range of infectious diseases worldwide, including H1N1, using
advanced proprietary virus-like-particle (VLP) technology. The
company produces potent VLP-based recombinant vaccines utilizing new and
efficient manufacturing approaches. Novavax is committed to using its
VLP technology to create country-specific vaccine solutions. The
company has formed a joint venture with Cadila Pharmaceuticals, named CPL
Biologicals, to develop and manufacture vaccines, biological therapeutics and
diagnostics in India. Additional information about Novavax is
available on the company’s website: www.novavax.com.
Cautionary
Note Regarding Forward-Looking Statements
Statements
herein relating to future performance, conditions or strategies and other
matters, including expectations regarding the development of the Company’s
vaccines, are forward-looking statements. Novavax cautions that these
forward-looking statements are subject to numerous assumptions, risks and
uncertainties, which change over time. We caution readers not to
place significant reliance on the forward-looking statements contained in this
release. Factors that may cause actual results to differ materially
from the results discussed in forward-looking statements or historical
experience include, among other things, the following including
the Company’s ability to progress its product candidates in preclinical or
clinical trials; clinical trial results; even if the data from preclinical
studies or clinical trials is positive, the product may not prove to be safe and
efficacious; the rate and progress of manufacturing scale-up; and the Company’s
ability to obtain adequate financing in the future through product licensing,
co-promotional arrangements, public or private equity or debt financing or
otherwise, and other factors referenced herein. Further information
on the factors and risks that could affect Novavax’s business, financial
conditions and results of operations, is contained in Novavax’s filings with the
U.S. Securities and Exchange Commission, which are available at www.sec.gov,
including the factors discussed under the caption "Risk Factors" in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by
our Quarterly Report on Form 10-Q for the quarters ended March 31,
2010. These forward-looking statements speak only as of the date of
this earnings release and Novavax assumes no duty to update such
statements.